A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Completed · Phase 3

Conditions studied: Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

In brief

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.

Key facts

Study ID

NCT05803421

Run by

Eli Lilly and Company

People needed

2749

Starts

2023-04-03

Expected to finish

2026-03-16

Last updated by the study team

2026-04-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have been diagnosed with type 2 diabetes mellitus (T2DM)
• Are at least 18 years of age or legal age of consent in the jurisdiction in which the study is taking place, whichever is older.
• Have HbA1c at screening
• ≥7.0% and ≤10.5% if background diabetes medication does not include a sulfonylurea, or
• ≥7.5% and ≤10.5% if background diabetes medication includes a sulfonylurea.
• Are on stable treatment of at least 1 and no more than 3 oral antihyperglycemic drugs for at least 90 days before screening. Antihyperglycemic drugs may include metformin, SGLT-2 inhibitors, and/or sulfonylureas
• Have increased risk for cardiovascular (CV) events due to:
• Coronary heart disease
• Peripheral arterial disease, presumed to be of atherosclerotic origin
• Cerebrovascular disease, presumed to be of atherosclerotic origin
• Chronic kidney disease (CKD)
• Congestive heart failure (CHF) New York Heart Association (NYHA) functional classification II to III
• Are of stable weight (± 5%) for at least 90 days prior to screening
• Have a BMI ≥25 kilograms per meter squared (kg/m2) at screening

You may not qualify if…

• Have type 1 diabetes mellitus
• Have had chronic or acute pancreatitis any time prior to screening
• Currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema (e.g. laster photocoagulation or intravitreal injections of anty-VEGF inhibitors
• Have a known clinically significant gastric emptying abnormality
• Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or blood alanine transaminase (ALT) or aspartate aminotransferase (AST) enzyme level ≥5.0 times the upper limit of normal (ULN) for the reference range, as determined by the central laboratory
• Have had any of the following within 60 days prior to screening: acute myocardial infarction, cerebrovascular accident (stroke), or hospitalization for congestive heart failure
• Have an eGFR <15 mL/min/1.73 m2 as determined at screening
• Have a family (first-degree relative) or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
• Have been taking any other diabetes medicines other than metformin, SGLT-2 inhibitors, and/or sulfonylureas during the last 90 days
• Have used any weight loss drugs, including herbal or nutritional supplements, within 90 days of screening

Where it is running

• Alliance for Multispecialty Research, LLC — Mobile, Alabama, United States
• Cahaba Research - Pelham — Pelham, Alabama, United States
• Syed Research Consultants Llc — Sheffield, Alabama, United States
• The Institute for Liver Health — Chandler, Arizona, United States
• Aventiv Research — Mesa, Arizona, United States
• Arizona Liver Health - Peoria — Peoria, Arizona, United States
• Elite Clinical Studies, LLC — Phoenix, Arizona, United States
• Absolute Clinical Research — Phoenix, Arizona, United States
• Clinical Research Institute of Arizona (CRI) - Sun City West — Sun City West, Arizona, United States
• Alliance for Multispecialty Research, LLC — Tempe, Arizona, United States
• Orange Grove Family Practice — Tucson, Arizona, United States
• KLR Business Group, Inc. dba Arkansas Clinical Research — Little Rock, Arkansas, United States
• Hope Clinical Research, Inc. — Canoga Park, California, United States
• Valley Clinical Trials, Inc. — Covina, California, United States
• Neighborhood Healthcare Institute of Health — Escondido, California, United States
• Valley Research — Fresno, California, United States
• Orange County Research Center — Lake Forest, California, United States
• Ark Clinical Research — Long Beach, California, United States
• Pacific Clinical Studies — Los Alamitos, California, United States
• Velocity Clinical Research, Los Angeles — Los Angeles, California, United States
• Infinity Clinical Research - Norco — Norco, California, United States
• Velocity Clinical Research, North Hollywood — North Hollywood, California, United States
• Valley Clinical Trials, Inc. — Northridge, California, United States
• Rancho Cucamonga Clinical Research — Rancho Cucamonga, California, United States
• Alliance for Multispecialty Research, LLC — Daphne, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.